Trial Profile
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 30 Mar 2020 Status changed from active, no longer recruiting to completed.
- 11 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2019 Planned End Date changed from 27 Jan 2019 to 1 Mar 2020.